🌎 Qiagen N.V. is a Dutch holding company and global provider of molecular diagnostics and life sciences solutions.
Core activities:
Sample processing technologies: Extraction and processing of DNA, RNA, and proteins from blood, tissue, and other materials.
Analysis technologies: Preparation of biomolecules for analysis.
Bioinformatics: Software and knowledge bases for data interpretation and practical applications.
Key products and platforms:
QuantiFERON: A test for the diagnosis of latent tuberculosis
QIAstat-Dx: A syndromic testing system for the simultaneous detection of a broad range of pathogens
QIAcuity: A digital PCR system
QIAGEN Digital Insights (QDI): A bioinformatics division
The company serves more than 500,000 customers worldwide in the life sciences (academic institutions, pharmaceutical R&D, forensic medicine) and molecular diagnostics.
In the second quarter of 2025, revenue reached $533.54 million, exceeding the consensus estimate.
The company expects to achieve its mid-term adjusted operating margin target of 31% by 2025, above its initial 2028 guidance.
Management increased its full-year 2025 adjusted earnings per share guidance to approximately $2.35 per year from the previous $2.28.
In 2025, Qiagen received CE-IVDR certification for its entire QIAstat-Dx portfolio in Europe and US FDA approval for the QIAstat-Dx Rise system.
The stock is trading broadly sideways at the upper end of the channel.
Core activities:
Sample processing technologies: Extraction and processing of DNA, RNA, and proteins from blood, tissue, and other materials.
Analysis technologies: Preparation of biomolecules for analysis.
Bioinformatics: Software and knowledge bases for data interpretation and practical applications.
Key products and platforms:
QuantiFERON: A test for the diagnosis of latent tuberculosis
QIAstat-Dx: A syndromic testing system for the simultaneous detection of a broad range of pathogens
QIAcuity: A digital PCR system
QIAGEN Digital Insights (QDI): A bioinformatics division
The company serves more than 500,000 customers worldwide in the life sciences (academic institutions, pharmaceutical R&D, forensic medicine) and molecular diagnostics.
In the second quarter of 2025, revenue reached $533.54 million, exceeding the consensus estimate.
The company expects to achieve its mid-term adjusted operating margin target of 31% by 2025, above its initial 2028 guidance.
Management increased its full-year 2025 adjusted earnings per share guidance to approximately $2.35 per year from the previous $2.28.
In 2025, Qiagen received CE-IVDR certification for its entire QIAstat-Dx portfolio in Europe and US FDA approval for the QIAstat-Dx Rise system.
The stock is trading broadly sideways at the upper end of the channel.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.